Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity

Fig. 2

Inflammation-induced parvalbumin deficit at P10 was ameliorated by montelukast. Immunohistochemistry for parvalbumin was used to assess the capacity of montelukast to ameliorate histopathological changes associated with the GM (A). Inflammation induced a decrease in parvalbumin interneurons in the barrel cortex, which was restored by 30 mg/kg montelukast treatment, with cell densities returning to control levels (B). This reduction in cell number was not accompanied by a change in branching of the remaining cells (C). No change with inflammation or montelukast treatment was seen for hippocampal parvalbumin interneurons (D). Data presented as mean ± SEM, *p < 0.05, **p < 0.01. Scale bars: A = 500 µm; SAL: saline (n = 6); IL1: IL-1β (n = 8); IL + MO: IL-1β + montelukast (n = 6); MO: montelukast (n = 5)

Back to article page